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Abstract Natural killer (NK) cells play a crucial role in
early immune response against cytomegalovirus infection.
A large and mounting body of data indicate that these cells
are involved in the regulation of the adaptive immune
response as well. By using mouse cytomegalovirus
(MCMV) as a model, several groups provided novel
insights into the role of NK cells in the development and
kinetics of antiviral CD8? T cell response. Depending on
infection conditions, virus strain and the genetic back-
ground of mice used, NK cells are either positive or neg-
ative regulators of the CD8? T cell response. At present,
there is no unique explanation for the observed differences
between various experimental systems used. In this review
we discuss the mechanisms involved in the interplay
between NK and CD8? T cells in the early control of
MCMV infection.
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Introduction
Cytomegaloviruses (CMVs) are species-specific herpes
viruses causing severe disease in immunocompromised or
immunologically immature hosts. Murine cytomegalovirus
(MCMV) is biologically similar to human cytomegalovirus
(HCMV) and is therefore the most frequently used model
for studying HCMV immunobiology and pathogenesis
[1, 2]. Both innate and adaptive immunity are involved in the
control of MCMV infection [1, 3, 4]. The innate immune
system is induced rapidly after infection without the need for
prior sensitization. The detection of virus infection is carried
out by Toll-like receptors (TLRs), which have the ability to
recognize the so-called pathogen-associated molecular
patterns (PAMPs) [5]. After recognizing viral PAMPs, TLR3
and TLR9, expressed primarily by dendritic cells (DC),
activate the NF-jB signaling pathway which triggers the
innate and adaptive immune response by inducing the pro-
duction of proinflammatory cytokines and the expression of
costimulatory molecules during MCMV infection [6, 7].
These early events drive the activation of natural killer
(NK) cells, the major effectors of innate immunity. NK cells
express an array of germ line-encoded receptors that transmit
either inhibitory or activating signals. The early activation of
NK cells upon MCMV infection results in cytokine pro-
duction and the release of cytotoxic granules containing
perforins and granzymes [8].
Based on their ability to mount an NK cell response to
MCMV, conventional mouse strains can be either MCMV-
resistant, such as C57BL/6 mice, or MCMV-susceptible,
such as BALB/c mice [1, 9]. In MCMV-infected C57BL/6
mice, NK cells are activated through Ly49H receptor
specific to the MCMV protein m157 [10, 11] leading to an
early control of viral replication [12, 13]. In contrast,
BALB/c mice lack the Ly49H receptor and are unable to
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mount an efficient NK cell response to MCMV [14] due to
the virus evading the NK-mediated control [15, 16]. For
instance, MCMV encodes proteins that can engage inhib-
itory NK cell receptors, thus avoiding the recognition of
infected cells by NK cells via the ‘‘missing self’’ axis [15].
In addition, in order to compromise NK cell activation,
MCMV uses other strategies such as downmodulation of
the ligands for activating receptors (e.g., NKG2D) [16, 17].
While NK cells restrict viral replication early upon
infection, CD8? T cells are important for the resolution of
primary infection and maintenance of virus latency [3].
The number of virus-specific CD8? T cells increases
through intensive proliferation followed by a contraction
phase and the generation of a stable pool of long-lived
memory CD8? T cells. Therefore, understanding the cel-
lular and molecular mechanisms involved in the priming
and maintenance of CD8? T cell response is of uttermost
importance for the development of CD8? T cell–based
immunotherapy and vaccines. In recent years, significant
progress has been made in understanding the role of NK
cells and other innate immune response mechanisms in the
regulation of the magnitude and longevity of antigen-spe-
cific CD8? T cell response (reviewed in [18]).
Innate regulation of the CD81 T cell response
Activation of NK cells depends on an intricate balance of
signals transmitted through their activating and inhibitory
receptors [19]. In addition, NK cell activation is induced by
proinflammatory cytokines such as type I interferons
(IFNs) and interleukin-12 (IL-12) secreted by DCs upon
MCMV infection [20]. Interferon gamma (IFN-c) produc-
tion by NK cell is induced by IL-12, whereas NK cell
cytotoxicity is stimulated by type I IFNs [21]. It has been
shown that in the early phase of MCMV infection, IFN-a
and IL-12 production is dependent on MyD88/TLR9 sig-
naling, whereas in the later phase of infection, IFN-a
production is maintained in the plasmacytoid DCs (pDCs)-
and MyD88-independent manner. In addition, in the latter
phase of MCMV infection, IFN-c production by NK cells
is decreased due to a reduced accessibility of IL-12 [22].
The adaptive immune response is linked to innate
immunity by activation of the cells of the adaptive immune
system: T and B lymphocytes. The mechanism relies on
antigen presentation by antigen-presenting cells (APCs)
and specific cytokines produced by various innate cells.
DCs are professional APCs due to their powerful capacity
to prime naive CD8? T cells upon MCMV infection [23].
This process of antigen presentation, in the context of
MHC class I molecules, can be achieved in two ways: The
direct or endogenous presentation is mediated by proteins
that are synthetized and processed by infected DCs and
other APCs. In contrast, cross-presentation is performed by
APCs that have endocytosed, processed and presented a
foreign antigen on MHC class I molecules (e.g., from cells
undergoing apoptosis) [24]. In addition to their essential
contribution in priming of naive CD8? T cells, DCs also
cross talk with NK cells during MCMV infection [6, 25].
During this communication, DCs-derived cytokines induce
NK cell activation. In addition, NK cells may enable the
maintenance of DCs population during infection [26].
Thus, by influencing DCs function, NK cells can regulate
development of specific immune response and eventually
the outcome of a MCMV infection.
NK cells shape the CD8? T cell response to MCMV
In addition to the well-established NK-DC cross talk during
MCMV infection, a number of studies provide ample evi-
dence for an interplay between NK cells and CD8? T cells
(reviewed in [15, 18]). Several studies have demonstrated
that the effectiveness of the NK cell response determines
the quality of the subsequent CD8? T cell antiviral
response [27–33]. Various murine models have been uti-
lized in order to demonstrate the role of NK cells in
shaping the antiviral CD8? T cell response. While in some
studies it has been shown that a strong NK cell response
results in an impaired CD8? T cell response [27, 29, 30,
33], other studies suggest that a strong NK cell response
can result in an enhanced CD8? T cell response [28, 31,
32]. These apparent discrepancies stem from differences in
the genetic background of mouse strains used, the com-
position of innate immune receptors involved and the viral
regulation of the immune response.
The study by Su and colleagues was first to report the
immunoregulatory function of NK cells during early
MCMV infection [27]. The absence of NK cells during
MCMV infection resulted in an enhanced CD8? T cell
response characterized by IFN-c production, BrdU incor-
poration and cell expansion. Andrews and colleagues have
also shown that NK cell activation via the Ly49H receptor
limits both the generation and long-term efficacy of specific
T cells by altering the frequency and duration of infection of
APCs [30]. In line with these data, we have also demon-
strated that the requirement for the CD8? T cells in the
control of early MCMV infection of C57BL/6 mice inver-
sely correlates with the capacity of NK cells to restrict viral
replication via the Ly49H receptor (Fig. 1) [33]. The fre-
quencies of epitope-specific CD8? T cells and their acti-
vation status were higher in mice infected with virus lacking
m157 (Dm157 MCMV), and therefore resistant to NK cell
response, compared to mice infected with NK cell–sensitive
virus (wild-type (WT) MCMV). Furthermore, we have
shown that the infection of C57BL/6 mice with Dm157
MCMV resulted in a higher virus load during the first few
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days post-infection (p.i.) accompanied by a higher fre-
quency of infected conventional DC (cDC). In addition, a
higher virus load resulted in a dramatic increase in proin-
flammatory cytokines, which could contribute to an
enhanced CD8? T cell response [29, 33]. The immuno-
regulatory role for NK cells in limiting CD8? T cell
response and modulation of virus-induced disease was also
demonstrated in lymphocytic choriomeningitis virus
(LCMV) infection [34, 35]. These studies showed that,
depending on the infection conditions and the virus dose
used, NK cells can limit the CD8? T cell response to LCMV
by preventing virus clearance and promoting viral persis-
tence. As demonstrated by Waggoner and colleagues, the
impaired CD8? T cell response to LCMV is a consequence
of NK cells killing of the activated CD4? T cells. Upon
infection with a high virus dose, NK cells dampen immune
pathology by supporting CD8? T cell exhaustion and viral
persistence, whereas during infection with a medium virus
dose, the presence of NK cells leads to CD8? T cell–
mediated pathology and death [34]. The study by Lang and
colleagues further supports the concept of negative regu-
lation of the CD8? T cell response to LCMV by NK cells.
Although NK cells did not exert a direct antiviral effect on
virus replication during LCMV infection, the activation
through the NKG2D receptor led to the killing of CD8? T
cells in perforin-dependent manner, thus enabling viral
persistence and immunopathology [35].
In a sharp contrast to the above-described inhibitory role
of NK cells in governing the virus-specific CD8? T cell
response, several reports demonstrated the ability of NK
cells to accelerate [28] or enhance the CD8? T cell
response [31, 32]. Robbins and colleagues have shown that
NK cell activation via interaction between the Ly49H
receptor and its viral ligand on infected cells may accel-
erate CD8? T cell response in vivo [28]. According to the
scenario proposed by the authors, the activation of NK cells
via this axis limits IFN-a/b production by pDCs and con-
sequently prevents the depletion of splenic cDCs causing a
prompt induction of the CD8? T cell response. Another
study has demonstrated that the recognition of infected
cells by licensed Ly49G2? NK cells also results in a faster
recovery of splenic cDCs and an enhanced antigen-specific
CD8? T cell response [32].
Data from our laboratory also indicate that the impact of
NK cells on subsequent CD8? T cell response cannot be
explained only by the differential efficacy of virus control.
The recombinant MCMV expressing RAE-1c, a cellular
ligand for the activating NK cell receptor NKG2D [36], has
CD8+ T-cell response
Δm157
NK-cell resistant virus
WT
NK-cell sensitive virus
0 4 7DAYS p.i. 1.5
NK cell response
Viral load
NK cell depletion
No depletion
Viral load
NK cell depletion
No depletion
IFN-γ Granzyme 
Fig. 1 Early control of MCMV infection by NK cells negatively
regulates the CD8? T cell response. Infection of C57BL/6 mice with
NK cell–sensitive virus results in limited CD8? T cell response as a
consequence of early restriction of viral replication by NK cells
activated through Ly49H–m157 interaction, already on day 1.5 p.i. In
contrast, infection of C57BL/6 mice with NK cell–resistant virus
induces a strong CD8? T cell response as early as 4 days p.i. and
reaches the peak on day 7 p.i. This enhanced CD8? T cell response is
characterized by an increased proliferation measured by BrdU
incorporation, a high frequency of IFN-c (red dots) producing
CD8? T cells stimulated with MCMV peptides in vitro, and the
upregulation of the activation marker granzyme B (blue dots) [33]
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shown a dramatic NK cell–dependent early attenuation, but
still the CD8? T cell response to a variety of viral epitopes
was equal or even stronger than in mice infected with WT
MCMV [31]. Although there is no simple mechanistic
explanation for the observed different outcomes in the
above studies, it should be taken into account that the
Ly49H receptor is exclusively expressed on NK cells [37],
and the reduced CD8? T cell response observed after WT
MCMV infection could be a consequence of a reduced
antigenic load. In contrast, NKG2D is also expressed as a
costimulatory molecule on CD8? T cells, suggesting that
the engagement of this receptor by RAE-1c expressed on
infected DCs could contribute to an enhanced priming of
CD8? T cells regardless of the level of antigenic load [31].
To address the impact of NK cell activation other than
via the Ly49H and NKG2D receptors, we have used
MCMV which lacks m04, one of the three MCMV-derived
glycoproteins that targets the MHC class I molecules [38].
Unlike m06 and m152, m04 does not downregulate MHC
class I molecules, but instead, it rescues cell surface MHC
class I molecules in order to engage the inhibitory Ly49
receptors [39, 40]. Therefore, the virus lacking m04 cannot
prevent NK cells activation and virus control via the
‘‘missing self’’ mechanism [39]. We have now evidence
that in spite of an early attenuation, Dm04 MCMV induces
a potent CD8? T cell response, which is essential for virus
control in the spleen on day 7 p.i. (Fig. 2). Thus, unlike the
Ly49H-dependent virus control in C57BL/6 mice, NK cell
activation and virus control via the ‘‘missing self’’ axis
upon infection of BALB/c mice with MCMV lacking m04
does not affect the development of the CD8? T cell
response in vivo. Yet, CD8? T cells were less important for
virus control in salivary glands (SG), indicating that
different organs display a different need for CD8? T cells
in MCMV control (Fig. 2).
Altogether, the above-presented scenarios of NK cell
modulation of primary CD8? T cell response to MCMV
point to a complex set of host and viral interactions.
NK cells determine the dynamics of CD8? T cell
response to MCMV in different organs
It is well established that the dynamics of MCMV control
in vivo is determined by various factors including the route
of infection and the virus source. NK cell–mediated control
of MCMV replication also varies between different organs
[41]. Although both cytolytic and noncytolytic mechanisms
contribute to NK cell–mediated antiviral control of MCMV
infection, their contribution may vary in different organs
[42]. The deletion of m157 resulted in a dramatic loss of
MCMV control on day 3 p.i. in several organs of C57BL/6
mice but did not abolish virus control in liver [12], sug-
gesting a different mechanism of virus control in this organ
[41, 42].
The dynamics of virus control in SG is particularly
informative and may depend on the virus source, route of
infection as well as the timing after infection. We have
shown previously that, unlike most of other organs, CD8?
T cells are unable to terminate productive infection in SG
[43]. Moreover, MCMV control in SG requires CD4? T
cells [44, 45]. As reported recently, virus replication in
different cellular compartments in SG can be explained by
different immune response mechanisms involved in virus
control [46].
A more recent work conducted in our laboratory also
illustrates the differential requirements of immune
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Fig. 2 NK cell activation via the ‘‘missing self’’ mechanism does not
compromise CD8? T cell response to MCMV. BALB/c mice were
intravenously (i.v.) injected with 2 9 105 plaque-forming units (PFU)
of either WT or Dm04 MCMV. For in vivo depletion of CD8 T cells,
mice were intraperitoneally (i.p.) injected with 300 lg of purified
monoclonal antibody (mAb) to CD8 (YTS 169.4) on days 1 and 5 p.i.
Control groups were treated with phosphate-buffered saline (PBS). On
day 7 p.i., viral titers in indicated organs were determined by the plaque
assay. Circles represent the titers of individual mice, and horizontal
bars represent the median values. Dotted line, detection limit
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response mechanisms in the control of MCMV in different
tissues ([33] and Fig. 3). CD8? T cells are not required for
MCMV control in spleen on day 3 p.i., and their contri-
bution at later time points is determined by the ability of
NK cells to contain virus replication during the early days
p.i. (Fig. 3). When C57BL/6 mice were infected with NK
cell–resistant virus, the inability of NK cells to control
virus replication was compensated by the CD8? T cells
which became essential for MCMV control on day 7 p.i.
Yet, at 2 weeks p.i., neither CD8? T cells nor NK cells are
indispensable for MCMV control in the spleen, suggesting
a robust physiological plasticity of the immune response.
MCMV control in SG is even more complex [45, 47,
48]. Our study demonstrated that NK cell–mediated anti-
viral control in SG is dependent on the Ly49H–m157
interaction [33]. This might suggest that the absence of a
strong NK cell control mediated through Ly49H–m157
interaction is providing the virus with the opportunity to
reach the acinar glandular epithelial cells and establish
persistent infection. Although our previous results suggest
against the role of CD8? T cells in control of persistent
infection in SG [43], recent studies from our laboratory
clearly demonstrated that CD8? T cells play a role in the
antiviral control in SG during the early days p.i. This is
illustrated by a dramatic effect of the CD8? T cell deple-
tion on virus titer in SG on day 7 p.i. with NK cell–resistant
MCMV (Fig. 3 and [33]). Notably, it appears that the route
of infection may also influence the requirements for CD8?
T cells in virus control in SG. In contrast to dramatic effect
of CD8? T cell depletion on virus control in SG in mice
infected intravenously [33], CD8? T cell depletion after
intraperitoneal infection had only minor effect on virus
control in this organ (Fig. 3). These new data, showing that
the virus replication in SG on day 7 p.i. is also mediated
through CD8? T cells, are—at a first glance—in a sharp
contrast to the previously published work showing that
MCMV control in SG is primarily CD4? T cell dependent
[43]. Our unpublished data indicate that antiviral control in
SG is CD8? T cell dependent only during the early p.i.
period, before the virus enters the acinar glandular epi-
thelial cells [44]. Therefore, it is likely that the cellular
compartment in SG colonized by virus during the early
days p.i. is under CD8? T cell control, whereas CD4? T
cells become essential when the virus reaches the acinar
glandular epithelial cells [49].
The role of TNFR type I and IFN type I signaling
on the regulation of the CD81 T cell response to MCMV
NK cells utilize several mechanisms to exert their antiviral
functions. Direct antiviral activity can be achieved through
cytotoxic mechanisms and the production of effector
cytokines such as IFN-c and tumor necrosis factor alpha
(TNF-a) [50–52]. The immunoregulatory function of NK
cells during MCMV infection, such as maintaining DCs
population, and thus regulation of antigen presentation, can
also be achieved through the production of effector cyto-
kines. The members of TNF-receptor (TNFR) superfamily
are expressed by different immune cells and, depending on
the cell type, can trigger differentiation, proliferation,
activation or cell death [53]. The TNFR type I (TNFRp55)
Virus titer (log10PFU)PBS
α-CD8
Spleen
day 3 p.i.
WT
Δm157
Salivary gland
day 14 p.i.
WT
Δm157
day 7 p.i.
WT
Δm157
2 3 4 2 3
Fig. 3 The requirement for the CD8? T cells in MCMV control is
determined by the strength of the NK cell response. C57BL/6 mice
were i.p. injected with 2 9 105 PFU of either WT or Dm157 MCMV.
On days 1, 5 and 12 p.i., mice were i.p. injected with PBS or depleting
anti-CD8 mAb. On days 3, 7 and 14 p.i., mice were killed and viral
titers in indicated organs were determined by plaque assay. Data are
presented as mean ± standard error of the mean (SEM). Dotted line,
detection limit
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signaling is rapid and highly specific and triggers activation
of caspase, leading to the apoptotic cell death [54]. It has
been shown that CMV infection inhibits signaling and
decreases the expression of TNFRs [55, 56]. To assess the
role of TNFRp55 in the development of CD8? T cell
response to early MCMV infection, we have infected mice
lacking TNFRp55 (B6.TNFRp55-/- mice) with either NK
cell–sensitive or NK cell–resistant MCMV and analyzed
viral titers on day 7 p.i. Similar to normal C57BL/6 mice,
B6.TNFRp55-/- mice efficiently controlled NK cell–sen-
sitive virus in the spleen, whereas the control of NK cell–
resistant virus required the activity of the CD8? T cells
(Fig. 4). Interestingly, B6.TNFRp55-/- mice were unable
to completely clear NK cell–resistant virus from the SG on
day 7 p.i., suggesting that NK cell–dependent virus control
in SG is partially mediated through this receptor [57].
Type I IFNs are also important regulators of the immune
response to different viral infections [20, 58]. Specifically,
it has been shown that IFNa/b is potent inducer of NK cell
cytotoxicity upon MCMV infection [59]. Previous studies
demonstrated that mice lacking IFNa/b receptor (IFNa/
bR-/-) exhibit a deficiency in homeostatic NK cell num-
bers, proliferation and killing capacity [60, 61]. In addition,
a recent study by Geurs and colleagues showed that the
engagement of Ly49H receptor after MCMV infection
compensated to some extent the deficient NK cell
proliferation observed in B6.IFNa/bR-/- mice, although
the overall proliferation of NK cells in these mice was still
reduced compared to C57BL/6 control mice [62]. Having
in mind the above-mentioned NK cell deficiency of
B6.IFNa/bR-/- mice, one might speculate that the
immunoregulatory function of NK cells in shaping the
subsequent CD8? T cell response to MCMV is also com-
promised. To address this issue, we have infected B6.IFNa/
bR-/- mice with either NK cell–sensitive or NK cell–
resistant MCMV and analyzed viral titers on day 7 p.i.
Similar to previously published work, the infection of
B6.IFNa/bR-/- mice with NK cell–sensitive MCMV strain
resulted in an efficient virus control on day 7 p.i., whereas
the absence of Ly49H engagement upon infection with NK
cell–resistant MCMV completely abolished any antiviral
control ([62] and Fig. 4). Contrary to normal C57BL/6
mice, which were able to control NK cell–resistant virus on
day 7 p.i. by CD8? T cells, in B6.IFNa/bR-/- mice this
antiviral control was abolished. Thus, the data suggest that
type I IFNs play an important role in enhanced CD8? T
cell response under conditions of insufficient early NK cell
antiviral control. The insufficient antiviral activity of CD8?
T cells in B6.IFNa/bR-/- mice was not unexpected, giving
that the type I IFNs play important role in induction of
CD8? T cell response upon viral infection by upregulating
the expression of MHC class I and costimulatory molecules
on APCs, providing the ‘‘third signal’’ required for acti-
vation of naive CD8? T cells and greatly augmenting their
proliferation [63–66]. Altogether, we have shown that IFN
type I signaling plays a major role in development of a
strong CD8? T cell response on day 7 p.i. with NK cell–
resistant MCMV, whereas TNFRp55 signaling is dispens-
able for it.
Conclusion
The currently available body of data demonstrate that the
impact of NK cells on specific CD8? T cell response
depends on numerous host and viral factors, including virus
sensitivity to NK cell control, mode of NK cell activation,
route of infection and host genetic factors. A better
understanding of how NK cells and other innate immune
response mechanisms regulate the generation and mainte-
nance of virus-specific CD8? T cell response is essential
for designing new strategies in antiviral therapy and in the
rational vaccine design.
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